In the third part of our analysis, we look at the markets that saw the best performance for pharma products during 2020 as well as modern portfolio theory (MPT) considerations and its deficiencies when applied to the structured product ecosystem.
In terms of products with calculated annualised performance, Germany saw an improvement in the performance of its products (from -5.52% to 0.2%, which is a 103.62% rise). In contrast, Austrian returns remained in negative territory yet losses in 2020 were more subdued (-6.59% in 2019 to -0.43% losses in 2020, indicating that performance soared by 93.51%). The UK, Czech Republic, Norway and Ireland were amongst the markets that saw their returns falling off a cliff ( figure 28) . Overall, th
Continue reading with a subscription to the SRP market intelligence platform.
Request DemoAlready a subscriber? Login